Decreased risk of nosocomial transmission of hepatitis B virus and hepatitis C virus among hemodialysis patients from southern Bulgaria

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Re-engagement of formerly incarcerated people living with HIV lost to care

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Metabolic co-morbidities among people living with HIV (PLWH) in an urban specialist HIV clinic in the United Kingdom

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Impact of CRISPR-Cas gene cassettes on the packaging efficiency and transduction titer of lentiviral vectors

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

High levels of HIV-1 recombinants circulating in Portugal

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

CRISPR-Cas therapy towards a cure for HIV/AIDS

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

We need to talk about ART: a survey of clinicians and people living with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Economic evaluation of post-exposure prophylaxis-in-pocket (PIP) compared to pre-exposure prophylaxis (PrEP) for individuals with a low frequency of high-risk HIV exposures: a matched control study

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

The influence of concurrent low-dose oral calcium carbonate supplementation on steady state pharmacokinetics of once daily oral raltegravir

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Perceived knowledge, attitudes, and practices of major non-communicable diseases and their risk factors among people living with HIV in Rwanda

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Whole genome sequencing approach to identify HIV-1 drug resistance in clinical samples

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Immune responses after mpox infection or vaccination in a cohort of HIV-PrEP users

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Extinction of all infectious HIV in cell culture by the CRISPR-cjCas9 system

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Clinical impact of APOBEC mutations and prevalence in HIV antiretroviral resistance reports

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Ten years of HIV admissions at a tertiary infectious diseases centre: increased mortality and length of stay

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Update on transmitted resistances in treatment-naive patients in Spain (2022)

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Effect of HIV treatment milestones on the HIV care continuum and AIDS diagnoses in CoRIS (2005-2022).

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Cabotegravir/rilpivirine long-acting for HIV treatment in a real-life setting: data from an Italian monocentric cohort

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Prevalence and risk factors of sarcopenia among people living with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Quantification of HIV RNA in cerebrospinal fluid

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Altered gut microbiota composition in virologically suppressed HIV-infected individuals on antiretroviral therapy: implications for chronic inflammation and metabolic health

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

NeuMoDx HIV viral load failure in a large group of Mayotte patients: viral diversity is still a challenge

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Familiarity of primary care physicians and infectious diseases specialists with PrEP and their willingness to prescribe it in the MENA region

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Gut innate immunity dysregulation and T cells activation go in parallel during HIV immunopathogenesis

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

HIV-DNA minority mutations profile in long-term infected paediatric population

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Elimination of infectious HIV DNA by CRISPR–saCas9

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Provision of care among migrants and refugees in a tertiary care center in Romania

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Intersection of HIV, biological considerations and comorbidities in women living with HIV: impact of online independent medical education on physician knowledge and confidence

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

A retrospective review of equivocal HIV serology results at a London (UK) teaching hospital

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Endoscopic features of gastric cryptosporidiosis in patients with HIV

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

High level of archived and circulating HIV-1 drug resistance mutations in adolescents with suppressed and unsuppressed viral loads in Cameroon

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

The newly developed NeuMoDx HIV-1 quant assay compared to the established alinity m HIV-1 assay for routine viral load measurement

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

HIV prevalence rates amongst migrant sex workers in Europe

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

A framework to evaluate the effectiveness of models of care for people with HIV (PWH)

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Delayed HIV diagnoses in the West of Ireland

27/04 12:00

01a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)

Comparison of non-invasive methods and liver biopsy for detection of liver fibrosis associated with chronic hepatitis B

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Investigation of stanniocalcin-1 as a new biomarker in the detection of chronic hepatitis B associated liver fibrosis: a pilot study

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Distribution and relevance of hepatitis B genotypes in the general population of Slovakia

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

The characteristic of maternal HBV quasispecies is related to occult HBV infection of infants born to highly viremic mothers

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Repressed expression of human endogenous retroviruses HERV-K (HML-2) and HERV-9 in chronic hepatitis C patients with endogenous activation of the interferon system in the liver

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

New molecular assay for the detection and quantification of hepatitis B virus load in EDTA-plasma

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Is HBV RNA a promising biomarker in chronic hepatitis B?

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

In silico 3-D structural prediction and characterisation of hepatitis E virus RNA-dependant RNA-polymerase (RdRp) region for antiviral research

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

On the road to Hepatitis C elimination, the need for screening beyond risk factors

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis Delta virus variability in Italy

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis B associated with severe COVID-19: a nationwide cohort study in Sweden

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Diagnostic performance of two chemiluminescence immunoassays for the detection and quantification of hepatitis B virus surface antigen (HBsAg): a comparative study

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Surveillance of the zoonotic rat hepatitis E virus in rodents in Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Evaluation of RT-qPCR for the diagnosis of active hepatitis D virus (HDV) through a single-step approach

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Detection and quantification of hepatitis delta virus RNA by three different assays

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

An innovative strategy to relink into care patients with active HCV infection.

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Outbreak of acute hepatitis HCV in HIV-infected individuals

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Antibody coated liposomes for transmucosal vaccination

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Limited uptake of hepatitis D virus testing in people living with hepatitis B virus infection in Australia

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis B infection and immunity in Timor-Leste: a population-representative serological survey

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis C virus (HCV) screening in an emergency department (ED), an effective strategy to hepatitis C elimination

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Analytic validation of a lab-developed qPCR assay for fully-automated high-throughput detection of Rocahepevirus ratti (ratHEV)

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Predictive factors for progression of fibrosis in chronic HBV infection on the indeterminate phase

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

The newly developed NeuMoDx HBV Quant Assay compared to the established Alinity m HBV Assay in routine viral load measurement

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

The newly developed NeuMoDx HCV Quant Assay compared to the established Alinity m HCV Assay in routine viral load measurement

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Prevalence of HDV infection in HBV positive patients from University Hospital in North Sardinia: updated data

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Performance of a new fully automated platform for HIV, HBV and HCV viral load assessment

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Evaluation and usefulness of rapid molecular assay for hepatitis C virus RNA detection

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

A large outbreak of hepatitis A in a northern community in Canada 2021-2022: public health interventions and immunisation in a remote context

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Evaluation of the virological profile of pregnant women infected with the hepatitis B virus treated at a referral center in Rio de Janeiro, Brazil

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Hepatitis E virus molecular surveillance in Hungary between 2018-2023 reveals infections with rare subtypes

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Profile of patients diagnosed with active HCV infection in an emergency department in Almeria, Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Opportunistic rescue of patients with HCV infection and lost in the healthcare system: results of the relink-C study in Almeria, Spain

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

3Hdtect-Q real-time PCR kit for simultaneous detection and differentiation of HIV, HCV and HBV in human plasma, serum and whole blood samples

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Is it cost-effective to implement double reflex testing strategy to diagnose hepatitis D-superinfection? Reflections from Sweden representing a country with low prevalence of hepatitis B and D viruses

27/04 12:00

1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)

Underdiagnosis of viral aetiologies in moderate-to-severe community-acquired pneumonia: an important clinical gap

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Phylogenetic lineage dynamics of global parainfluenza virus type 3 post-COVID-19 pandemic

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Nanobody-based PROTAC strategy provides broad-spectrum antiviral activity against porcine arterivirus

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Frequency of respiratory virus detection in the upper respiratory tract of hospitalised patients

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Beyond influenza and SARS-CoV-2: advancing respiratory sentinel surveillance in Sweden

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Prophylactic efficacy of CD388, a novel drug-Fc conjugate (DFC), in an influenza A/H3N2 human challenge model

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Clinical performance evaluation of two commercial antigen test kits for diagnosis of SARS-CoV-2, influenza A and influenza B infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Respiratory syncytial virus infections in recipients of bone marrow transplantations: a systematic review and meta-analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Influenza virus, SARS-CoV-2, respiratory syncytial virus, rhinovirus, adenovirus, bocavirus, and other respiratory virus circulation during 2022–2023 season in Latvia: focus on codetections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

The resurgence of influenza activity and out-of-season epidemics of RSV during the Omicron waves in Beijing, China

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Determination of RSV reinfection in a German population cohort between 2020 and 2023 using a newly established RSV antigen-derived 9-plex immunoassay (RSV MIA)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Risk of cardiovascular events after influenza: a population-based self-controlled case series study, Spain 2011-2018

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Evaluation and comparison of three case definitions for influenza detection in the same setting and population in the Valencia region of Spain

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Rapid intra-season waning of vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Consumer preferences for features of influenza vaccines in the United Kingdom: results from a discrete-choice experiment study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

General population and healthcare professionals' level of knowledge of the burden and prevention of respiratory syncytial virus and other respiratory infections in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

A generic, saliva-based PCR test for the detection of RSV offers a low-burden approach for sustainable surveillance of RSV

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

A nationwide retrospective cohort study to assess the relative vaccine effectiveness of high-dose compared to standard dose influenza vaccines in France during the 2021-2022 season: results of a complementary analysis of DRIVEN study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Comparison of efficacy and safety between baloxavir marboxil and oseltamivir in outpatients with uncomplicated influenza: a real-world study of more than 1,500 patients

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Clinical characteristics, complications, and predictors of serious outcomes among adult outpatients with respiratory syncytial virus infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: a meta-analysis of evidence from randomized trials

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Clinical assessment of a fully automated RT-PCR assay for the qualitative detection of parainfluenza virus 1,3 and 2/4 in human nasal/throat swabs under IVDR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Evaluation of the clinical performance of a fully automated RT-PCR assay for the qualitative detection of RSV and hMPV in human nasal/throat swabs and bronchoalveolar lavage under IVDR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Higher waist circumference was associated with reduced cellular immune response to influenza vaccine: findings from the DYNAMIC cohort study of older adults in Singapore

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Relative effectiveness of an adjuvanted influenza vaccine vs non-adjuvanted influenza vaccines in high-risk older adults during the 2019-2020 U.S. influenza season

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

A behaviour change techniques analysis, systematic review meta-analysis and meta-regression of communication-mediated interventions supporting influenza vaccination uptake in adults in primary care settings

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Cost-effectiveness of protective equipment stockpiles for reducing essential worker absenteeism in a pandemic: a modelling study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Increased 90 days mortality associated with RSV compared to influenza among adults in Denmark

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Isolation of monoclonal antibodies against human parainfluenza virus type 3 strains

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Galectin-3 regulates viral pathogenesis and inflammation in H5N1 and H7N9 avian influenza virus infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Quantitative analysis of FluNet surveillance data: has B Yamagata really gone extinct?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Comparison of three commercial nucleic amplification tests for influenza A testing in a symptomatic patient population

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

RSV circulation in the SARS-Cov-2 pandemic era in the north of Spain (Asturias)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Influenza A and B viral loads are higher in nasopharyngeal swabs compared to mid-turbinate swabs

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Spain

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Respiratory syncytial virus as single detection is associated with younger age and worse clinical outcomes

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Next-generation mRNA-based seasonal influenza vaccines including additional A/H3N2 strains: Phase 1/2 trial findings in adults aged 50-75 years

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Respiratory syncytial virus incidence trends during omicron COVID pandemic in older adults: a community-based prospective study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

The utility of multiplex real-time PCR screening for viral respiratory infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

A comparative study of the incidence, risk factors and outcome of hospitalised adults with RSV vs influenza A infection

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Tracking seasonal influenza trends in South Tyrol during season 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Enterovirus landscape in Barcelona: A virological surveillance journey through the 2020-2023 seasons in the shadow of the COVID-19 pandemics

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Seasonal trends in sentinel surveillance: a seven-year retrospective analysis from the Aegean region, Turkiye (2016-2023)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Unraveling the genetic, antigenic, and antiviral landscape of influenza viruses circulating in Catalonia (Spain) during the 2022-2023 season

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Identification of granzymes as crucial regulators and potential targets of influenza-associated immunopathology and superinfections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Severe manifestations of parainfluenza type 4 infections in children

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Decoding severity: the GIHSN SevScale for hospitalised ARI cases

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Assessing the cost-effectiveness and public health impact of the adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in Canadian older adults

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Do pregnant women get the flu shot? A view over Greece

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Mapping the trends of non-SARS-CoV-2 respiratory viruses: a 2016–2023 analysis in a Rome hospital microbiology laboratory

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Digitally facilitated access to information on influenza complications and its prevention: a multicentric study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Estimation of RSV-attributable mortality in adults in Italy between 2015 and 2019

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Modelling the health and economics benefits of a rapid vaccine intervention in an influenza pandemic in the United Kingdom

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Changes in influenzavirus-A/B and human respiratory syncytial virus seasonality and activity during the COVID-19 pandemic in Switzerland

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Estimated impact of delayed influenza vaccine strain selection on vaccine effectiveness: a descriptive and modeling study

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Nosocomial acquisition, a zoom on respiratory viruses (NAZARE): A laboratory-based surveillance study to explore epidemiology and risk factors

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Impact of community pharmacy vaccination services on vaccination coverage of immunocompromised patients against respiratory tract infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Estimating the health and economic burden of pneumococcal diseases attributable to V116 vs PCV20 serotypes among adults in Switzerland

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Molecular epidemiology of rhinovirus: genotypes detected during and after the COVID-19 pandemic

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Setting the bar for new generation influenza vaccine reactogenicity: expected clinical and cost tradeoffs compared to standard-of-care vaccines

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Validation of a genome sequencing protocol for influenza B viruses

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Diversification of the ON1 genotype of HVRS-A on the coast of Peru during 2009-2020

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

The clinical and economic value of MF59-adjuvanted quadrivalent influenza vaccination in the elderly in Argentina

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Hospital and community epidemiology of SARS-CoV-2, influenza and RSV during 2022/2023 season in Auvergne-Rhône-Alpes, France: a comparative analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Economic burden of respiratory syncytial virus (RSV) and unspecified lower respiratory tract infection (UBP) during RSV season in adults in Germany (2015-2018): a health claims analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Subtyping and whole-genome sequencing of influenza A/B viruses using pan-subtype primers, widely-used library prep reagents, and cloud-based data analysis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Impact of COVID-19 pandemic on influenza vaccination rates among healthcare personnel at a tertiary-care centre in Lebanon

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Molecular investigation of seasonal viral respiratory outbreaks

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Respiratory syncytial virus burden in older adults (≥ 60 years): a two-year Italian multicentre study in the late COVID-19 pandemic and early post-pandemic period

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Serological investigation of RSV antibody responses in UK healthcare workers (SIREN study)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Co-circulation of influenza, SARS-CoV-2 and RSV (tripledemic) among severe acute respiratory infection cases in the Philippines, 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Self-collected saliva demonstrates utility for influenza surveillance by extraction-free PCR

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Overview of adenovirus respiratory infections: preliminary findings of a multicentre study in Italy, 2022-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Modelling the impact on carbon emissions of using a high dose influenza vaccine instead of standard dose among 65 years and older adults in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Comparison of burden of respiratory syncytial virus hospitalisation in paediatric population during two consecutive seasons 2021-2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Early assessment of viral respiratory epidemics for the 2023/2024 season based on community laboratory surveillance network in France

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

A novel multiplex, quantitative immunoassay for anti-influenza IgG demonstrates individual variability in binding specificity targeting antigenically distinct haemagglutinin proteins

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Influenza like-illness surveillance using a Belgian sentinel network of nursing homes: results of October 2022 onwards

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Understanding antibody cross-reactivity between seasonal Influenza and H5N1 as a method to conduct H5N1-specific serosurveillance

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Serological responses to a boosted tetravalent influenza vaccine regimen in multiple myeloma patients: evaluating the impact of daratumumab treatment.

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Changing pattern of respiratory virus detection among severe acute respiratory syndrome corona virus: two symptomatic patients in the central province of Sri Lanka

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Investigating innovative system methods for the diagnosis of respiratory viruses for rapid clinical diagnosis

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Impact of hospitalisations due to respiratory syncytial virus in a highly complex public paediatric hospital in Brazil, between January 2021 and May 2023

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Tasmania's COVID mitigation strategies provide insights into respiratory syncytial virus evolution

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Trends and severity of parainfluenza virus infections over the past decade

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Further characterisation of vaccine efficacy in infants from a Phase 3 RCT of a bivalent prefusion F RSV vaccine administered during pregnancy

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Impacts on respiratory viruses among hospitalised children with respiratory diseases after lifting COVID-19 restrictions

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Pre-immunisation landscape of human respiratory syncytial virus: genomic insights from Catalonia's SIVIC programme in the era of neutralising monoclonal antibody deployment

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Neutralising monoclonal antibodies raised against highly conserved influenza hemagglutinin, neuraminidase, and matrix epitopes may offer novel cocktail therapeutic strategies

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Oxford Nanopore Sequencing revolutionizes Influenza surveillance in resource-limited settings

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Impact of influenza-related hospitalisation in Spain: characteristics and risk factor of mortality during five influenza seasons (2016 to 2021)

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

CD388, a drug-Fc conjugate, shows long half-life in early clinical studies

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Using nanopore amplicon sequencing data for rapid analysis of influenza type A

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Verification of the Savanna respiratory viral panel-4 as a rapid screening tool for respiratory viral infections

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

What was the burden of winter pressures on the UK SIREN healthcare worker cohort winter 2022-23?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Forecasting the epidemiological trends of pediatric acute respiratory infections at the community level using time series predictive models: an Italian scenario

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Evaluation of the performance of the Hologic Panther fusion 4 plex-assay

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

RSV viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Differences in influenza vaccination among healthcare workers: impact of work task, area of membership and gender

27/04 12:00

1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)

Age-sex patterns of human herpesvirus infection seroprevalences among hospitalised patients in Paris area, France, 2016 to 2022

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Cytomegalovirus reactivation in critically ill mechanically ventilated patients

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Validation of a herpes zoster conceptual model on quality of life in East Asia

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Clinical relevance of human herpesvirus-7 DNA detection in a tertiary care setting over a 13-year period

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Varicella-zoster virus circulating clades in a French tertiary referral centre, Paris, France, 2018-2023

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Oedema volume on admission may predict poor outcome in HSV-encephalitis, varies in reliability across aetiologies and lower oedema volumes

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Potential relationship between cytomegalovirus and immunosenescence: evidence from observational studies

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Incidence and risk factors for varicella-zoster virus central nervous system infections

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

The association between acyclovir-related neurotoxicity and its concentration

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Ganciclovir/valganciclovir therapy in congenital CMV infection: 24-year experience of a tertiary care children hospital in northern Italy

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

CMV plasma reactivation predicts CMV organ disease in patients with moderate to severe ulcerative colitis needing hospitalisation

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Immune response to human herpes virus in SARS-CoV-2 mild infection

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Review of laboratory testing and processing protocols for varicella zoster virus in a north London hospital

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Trends in hospitalisations related to herpes zoster in Denmark from 1998 to 2021

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

CMV infection in pregnancy: a 5-years clinical experience of the regional reference center for infections in pregnancy in a low-birth Italian region

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Management of CMV primary infection in pregnancy and neonatal outcome in the era of valacyclovir treatment: a monocentric prospective study

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Comparison of two IVDR molecular diagnostic assays for the detection of HSV-1, HSV-2 and VZV in lesions and ulcers.

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Cytomegalovirus infection in patients hospitalised in intensive care

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Herpetic gingivostomatitis caused by human herpesvirus type 7: a new entity?

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

The role of Epstein-Barr virus in children with post-acute sequelae of SARS-CoV-2 infection in Taiwan

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Development and clinical validation of extraction-free loop-mediated isothermal amplification assays for rapid detection and subtyping of herpes simplex virus

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

Antigen-specific immunoassays improve the serological staging of cytomegalovirus infection

27/04 12:00

1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

sST2 is a potential biomarker for early prognostication of severe dengue

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Steroid pulse therapy for severe fever with thrombocytopenia syndrome patients may not improve prognosis: retrospective analysis with overlap weighting using a national inpatient database

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Development of a clinical scoring system to make a presumptive diagnosis of Kyasanur Forest disease: a case-control study from South India

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Autochtonous dengue outbreak in Lombardy region, Italy, 2023: results of a seroprevalence study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Effect of montelukast in preventing dengue with warning signs among patients with dengue: a multicentre, randomised, double-blind, placebo-controlled trial

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Exploratory analysis of the knowledge, attitudes and perceptions of healthcare workers about arboviruses in the context of surveillance in the Republic of Guinea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

NS1-based IgG FcγR Enzyme-Linked Immunosorbent Assays allow serological differential diagnosis of dengue and zika virus infections in both returning travellers and individuals from endemic regions

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

NanoHarmony: unleashing silver's whisper in swift Zika detection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Factors associated with mpox vaccination willingness and uptake among men who have sex with men

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Intensified surveillance for tick-borne encephalitis to identify possible places of infection in Bavaria, Germany, May–October 2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Lassa virus: unravelling the within-host evolutionary dynamics of acute and persistent infections and the virulence evolution among hosts

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Correlation between the cycle threshold values of medium- and small-segment severe fever with thrombocytopenia syndrome virus and viral load: prognostic implications

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Do infectious diseases specialists and neurologists manage patients with tick-borne encephalitis differently?

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

A ‘living' rapid research needs appraisal platform for WHO priority diseases: henipavirus evidence-gaps

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Spatio-temporal distribution of Crimean-Congo hemorrhagic fever and the effect of climate factors and Eid ul Adha in Pakistan: a decade-long experience from tertiary care laboratory network

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Laboratory results of mpox suspected cases tested by differential diagnostic panel during the mpox outbreak in Hungary in 2022/2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Exploring mpox genome variations amidst the 2022 outbreak

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

First detection of the zoonotic rat hepatitis E virus in pigs

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical importance of Alongshan virus, a new tick-borne Flaviviridae virus: a retrospective serological and molecular study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Assessing the synergistic insecticidal activity of Syzygium aromaticum and Citrus aurantifolia leaf extract combination against Aedes vectors

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Orthopoxvirus differential diagnosis by neutralising antibodies in mpox patients and vaccinated individuals

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

MCP-3 as a prognostic biomarker for severe fever with thrombocytopenia syndrome: a longitudinal cytokine profile Study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Prospective evaluation of serum cytokines and musculoskeletal ultrasound as surrogate markers for chronic post-chikungunya rheumatism

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

A question from an endemic area: which diseases are included in the differential diagnosis with CCHF?

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Increased likelihood of leukopenia, thrombocytopenia, and other characteristics in Crimean-Congo haemorrhagic fever patients: a systematic review and analysis of clinical factors that indicate infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Dengue vaccine: a risk model to prioritise and maximize the impact of a dengue vaccination program in Peru

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mayaro virus and chikungunya virus IgM and IgG testing in parallel improves diagnosis of acute mayaro virus infections

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Epidemiology trends of infections and outbreaks of Crimean-Congo hemorrhagic fever worldwide, 2017-2023.

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Strengthening preparedness to arbovirus infections in Europe: a prospective, observational study in southeast Europe

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Expression of galectin-3 ameliorates zika virus infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Assessing the endemicity of Japanese encephalitis in central India: a comprehensive study of human and animals in Madhya Pradesh

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

A meta-analysis and mapping of global mpox infection among children and adolescents

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical presentation and viral shedding in patients with mpox in South Korea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical-laboratory features and predictive factors for sequelae of tick-borne encephalitis virus infection: a retrospective observational study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Tick of the iceberg: using a One Health approach to assess and respond to the threat of tick-borne encephalitis in England

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Relation of WNV seroprevalence with ABO and D blood groups among blood donors: implication for transfusion safety

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical and microbiological study of bacterial or fungal co-infections in severe fever with thrombocytopenia syndrome

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Enhancing clinical diagnosis of dengue: performance evaluation of NS1 antigen and IgG/IgM antibody tests

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mpox in Colombia: an analysis of the 4,114 PCR confirmed cases in June 2022-November 2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Co-detection of RNA and DNA viruses in a single library prep and enrichment workflow

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Results from a large-scale dengue diagnostic accuracy systematic review and meta-analysis: NS1 ELISA performs similarly to RT-PCR

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

TBE vaccination: insights from a KAB survey among Lyme borreliosis cases in Bavaria, Germany, 2019

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Children hospitalised with Crimean-Congo haemorrhagic fever in Turkiye have different clinical and diagnostic features and lower mortality than adults, implying that diagnostic criteria and illness severity scoring systems need adaptation for use in children

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Elevated plasma level of IP-10 /CXCL10 is correlated with severity of human West Nile virus (WNV) infection

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Effect of severe fever with thrombocytopenia syndrome virus genotype on disease severity, viral load, and cytokines in South Korea

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Clinical findings and IL-6 levels in patients with dengue

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Arthropod-borned zoonosis in Cádiz, south of Spain: serological prevalence in a high-risk group

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Development and validation of the PLNA score to predict cytokine storm in patients with acute phase of SFTS: a single-center cohort study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Hybrid capture-based next-generation sequencing: implementation for Lassa virus for the recovery of in-depth viral genomic data

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Development of a multiplexed serological mpox assay for diagnostics, serosurveillance, and immunology studies

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Genotypic diversity and molecular characterisation of DENV-2 in endemic areas of Peru during 2016-2021

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

The clinical characteristics of human mpox disease before and after the 2022 outbreak: any difference? a metaanalysis study

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Early identification of complex biomarker signatures predicting plasma leakage in dengue patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Genetic characteristics of aigai virus: a recently reclassified orthonairovirus

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Knowledge, risk perception and attitudes about mpox and the implementation of preventive measures in people belonging to the LGTBIQ+ community in Colombia

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Adjuvanted unconjugated highly conserved multi-epitope influenza peptide vaccine induced broadly reactive antibodies to multiple influenza viruses in pigs

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Investigating the pathogenesis of Middle East respiratory syndrome coronavirus infection using a quantitative phosphoproteomics approach

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Evaluation of viral load and neutralising antibody levels in Crimean-Congo hemorrhagic fever patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Nanopore sequencing of RdRp gene used as a genetic marker for characterization of coronaviruses in clinical samples

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Mpox experience at a tertiary infectious diseases centre in a tropical country between 2022-2023

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Combining phylogeographic and niche modelling approaches to investigate the ecological drivers of TBEV at the Palearctic scale

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Chikungunya in Colombia, 2022: An analysis of the cases notified to the National Surveillance System in the midst of South American reemergence

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Dengue epidemics in Colombia, 2023: an analysis of the cases notified to the national surveillance system

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Minor clinical sequelae and absence of viral persistence: an 8-month follow-up study of former mpox patients

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Sero-catalytic and spatial modeling of dengue force-of-infection from age-stratified seroprevalence data in Timor-Leste

27/04 12:00

1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)

Evaluation of clinical applicability for a novel ultrasensitive ELISA detection of dengue virus

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Performance analysis of a commercial meningitis/encephalitis panel compared to other microbiological tests and clinical diagnosis at discharge: a retrospective observational study of 1000 consecutive patients

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Consistent differences in analytical and clinical performance for detection of SARS-CoV-2, influenza A/B and RSV between point-of-care tests

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Biomarkers and genotypes in patients with central nervous system infection caused by enterovirus

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Concurrent assessment of three viral RNA pathogens in MK buffered solution using droplet digital PCR: performance comparison for diagnostic based detection

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Validation of a new molecular assay for the quantification of Epstein-Barr virus load in EDTA-plasma

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

A comparison of four molecular assays for the detection of mpox virus DNA

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Comparison between conventional primary HPV cervical screening vs by vaginal self-sampling in France

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

JC virus VP1 gene: a more accurate detection and quantification of viral DNA

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Performance evaluation test on rapid polymerase chain reaction test for mpox without nucleic acid extraction

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Verification of a new molecular point of care system for respiratory viruses for its use with two widely used transportation media

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Enhancing pathogen detection in viral respiratory tract infections among individuals aged >55 years through expanded PCR panel testing

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Comparison of three assays for the detection of human papillomavirus and their correlation with cervical cytology

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Validation of a multiplex qRT-PCR assay for RSV, influenza A/B and SARS-CoV-2

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Clinical performance evaluation of a real-time PCR-based test for the detection of high-risk HPV genotypes

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Establishing EBV load thresholds for predicting persisting EBV-DNAemia and associated disease

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Multicenter evaluation of the Standard M10 Influenza, RSV and SARS-CoV-2 assay in nasopharyngeal swabs in liquid Amies medium

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Comparison of Allplex HPV28 and Anyplex II HPV28 Assays for the detection and genotyping of human papillomavirus

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Urine-based HPV-DNA screening for cervical cancer prevention in a rural health clinic in Eswatini

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

A lateral flow test for rapid identification of paediatric viral infection based on host response mRNA transcripts

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Performance evaluation of the comercial BK virus ASR on the NeuMoDx system

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Clinical evaluation of an adenoviral species-typing model using PCR melt-curve data

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Molecular epidemiology of measles virus from measles outbreak in the Philippines, 2023

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

New approaches in laboratory surveillance in the face of polio threat for public health, Romania 2023

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Implementation of the allplex high risk HPV genotyping assay in a routine clinical lab

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Utilising digitally characterised control material to improve comparability of molecular workflows for viral gastroenteritis

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Validation of commercial real-time PCR kit for detection of mpox

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Diagnostic performance of five real-time PCR assays for mpox virus detection

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Urine and vaginal high-risk human papilloma virus (hrHPV) self-sampling among HIV-positive women in Guinea-Bissau is well-accepted: three in four women are HPV-positive

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Evaluating and expanding measles serological assays: toward an improved diagnostic tool

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Cerebrospinal fluid and plasma biomarkers in patients with central nervous system infections: a retrospective study

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Acute viral gastro-enteritis in infants and toddlers, from the big three to the big five?

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Identification of adeno-associated virus type 2 viremia in a large cohort from Berlin, Germany

27/04 12:00

1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Viral and inflammatory markers in sudden death caused by myocarditis: a retrospective bicentric study

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

HPV genotypes distribution in urethral samples in French men

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Molecular epidemiology of Coxsackie A6 strains circulating in Hungary between 2020-2023

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Epidemiological study of high-risk human papillomavirus before the advent of primary molecular screening in Occitania, France

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Cutavirus prevalence in malignant and non-malignant tissues

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

National diagnostics case series and One Health phylogenetic analysis of Murray valley encephalitis outbreak in Australia

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Molecular epidemiology of human papillomavirus in a lower-middle-income and cervical cancer high-burden country

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Patterns of enterovirus infections in hospitalisations and outpatient visits in Denmark 2015-2022

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Detection of different viruses of clinical importance in bone marrow

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Norovirus genotype distribution among children with acute gastroenteritis in South-East Austria

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

First results of laboratory surveillance for enteroviruses in Italy (2022-2023)

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Comprehensive genotyping supports the epidemiological investigation of Austrian measles virus outbreaks in 2023

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Rotavirus A epidemiology shifts due to pandemic: 14-year experience of Belgian National Reference Center in the COVID-19 context

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Circulation of respiratory viruses in hospitalised children in the post-COVID-19 era

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Negative conversion and recurrence rate of high risk human papillomavirus in cervical infection

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Rotavirus clinical and genomic surveillance reveals predominance of equine-like G3 strains, antigenic mismatches with vaccines, NSP2-reassortants and multiple vaccine breakthrough cases, 2021-2023, Madrid, Spain

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Male human papillomavirus genital infection: a focus on non-vaccine genotypes

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Analysis of human papillomavirus 51 (HPV51) genetic variations detected in women with cervical dysplasia

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Evaluation of biomarkers associated with human papillomavirus 16 (HPV16) persistent infection

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Understanding Measles Comeback

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Establishing a 24/7 mpox outbreak helpline: an overlooked source of early epidemiological data?

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Descriptive study of the distribution of human papillomavirus genotypes in a hospital in southern Spain

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Echovirus 11 reported in emilia-romagna region during 2023

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Contribution of rotavirus infections to child mortality in the Cchild health and mortality prevention (CHAMPS) network

27/04 12:00

1g. Viral epidemiology - general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

Dengue virus infection elicits galectin-3 expression with inhibitory impact on dengue viral infectivity

27/04 12:00

1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)

Detection of human polyomaviruses in oral samples supports the oral transmission route

27/04 12:00

1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)

Identification of viral inhibitors: evaluating Himalayan herbs as alternatives for dengue treatment

27/04 12:00

1i. Basic and applied virology (incl in vitro and in vivo models, novel methods)

Recently published randomised controlled trials investigating treatments against COVID-19 displayed lower risk of bias: a systematic review and critical appraisal

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Real-world safety and effectiveness of molnupiravir during the Omicron wave: a final report of a post-marketing surveillance in Japan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Drug interactions with nirmatrelvir/ritonavir in hospitalised patients: prevalence, severity and management strategies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Influence of cytokine levels on the effect of tocilizumab on mortality or ICU admission in COVID-19 pneumonia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long COVID looks like other post-viral syndromes 12 months after infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cross-sectional surveillance study of long COVID in Toyonaka city, Osaka Prefecture, Japan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The impact of the COVID-19 pandemic on adult vaccination, with emphasis on influenza and pneumococcal vaccination in India: a comprehensive report

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Healthcare workers' attitude toward COVID-19 vaccination campaign in Armenia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The predictors of COVID-19 immunogenicity elicited by vaccines against SARS-CoV-2 in bone marrow transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Improved SARS-CoV-2 molecular detection in European expert public health laboratories: results of the third external quality assessment, 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Normalisation of eosinophil count is predictive of reduced oxygen requirement during COVID-19 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Influence of anti-spike protein antibody levels on tocilizumab efficacy in hospitalised patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Unraveling the past: analysing the effects of COVID-19 on hematological malignancy patients - observations from 2020 to 2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Circulating antibody titres predict infection and severity in COVID-19 close contacts

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

First serological study of MERS-CoV on dromedary camels from Algeria

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cost-effectiveness of oral nirmatrelvir/ritonavir in patients at high risk for progression to severe COVID-19 in the United States

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Enhancing respiratory disease diagnosis: a comparative analysis of multiplex point-of-care PCR and antigen testing for SARS-CoV-2, influenza, and respiratory syncytial virus in Germany

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Antibody responses against recently emerged SARS-CoV-2 variants: a population-based cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

For COVID vaccination choices in Germany or the United Kingdom, efficacy ranks first followed by common side effects

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparison of characteristics between patients who received COVID-19 non-mRNA and mRNA vaccines in Germany

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Systematic review and meta-regression analysis of clinical therapeutic responses and viral clearance in early symptomatic COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prognostic of COVID-19 in ICU-admitted COPD patients: the impact of high-flow nasal cannulas and other factors

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Robust immune response to COVID-19 vaccination in Greenlanders: an observational study in an island population

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

To die with or to die for COVID-19 infection during the Omicron era

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Recurrent ventilator-associated pneumonia in severe COVID-19 ARDS patients requiring ECMO support

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Protective effect of previous omicron BA.2 infection and fourth dose vaccination on SARS-CoV-2 XBB infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

External validations of prognostic COVID-19 scores: an innovative mass validation using the multi-center ORCHESTRA cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Real-world evidence comparing the risk of Delta and Omicron infection outcomes by SARS-CoV-2 antibody levels

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Remdesivir reduces mortality in immunocompromised patients hospitalised for COVID-19 across the pandemic and endemic eras

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Efficacy of tofacitinib as add-on therapy to remdesivir and corticosteroids in COVID-19 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Proteomic and cellular characterisation of Omicron breakthrough infections and a third homologous or heterogenous boosting vaccination by a longitudinal cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Levels of inflammatory and cardiac biomarkers as a predictor factor for complications and outcomes in hospitalised COVID-19 patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Changes in Pneumocystis jirovecii pneumonia (PCP) before and during COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

SARS-CoV-2 breakthrough infections in healthcare workers of an Italian university hospital: an update three years after the start of the vaccination campaign

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cracking the SARS-CoV-2 Omicron variants: unveiling the sensitivity of rapid antigen tests and optimal sampling sites

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Vaccination shapes within-host SARS-CoV-2 diversity of Omicron BA.2.2 breakthrough infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

In vitro neutralisation of VYD222 against Omicron sublineages

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical outcomes of COVID-19 vaccine breakthrough infections: a single-centre study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Descriptive analysis of self-reported HRQoL using EQ-5D-5L among symptomatic outpatients with COVID-19 in the US during an Omicron predominant period

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical presentation of COVID-19 among healthcare workers across the early COVID-19 pandemic, Peru

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sentinel cohort safety of AZD5156/AZD3152 from the phase 1/3 SUPERNOVA trial for COVID-19 prevention in participants with immune impairment

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: qualitative results from the procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients (PEACH Study)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Descriptive epidemiology of adverse events following mRNA COVID-19 vaccination in Curacao

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Assessing transmission of SARS-CoV-2 via the aerosol and contact routes using a direct human totransgenic K18-hACE2 mouse model

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Antimicrobial resistance before, during, and after the COVID-19 pandemic, 120 U.S. Hospitals

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Retrospective study of baseline co-medication potential DDI in COVID-19 hospitalised patients in Spain: the COCOS Study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The gut microbiota as an early predictor of COVID-19 severity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients: the PEACH study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Effect of co-formulation on pharmacokinetics of AZD7442, a monoclonal antibody combination against COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVID-19 pandemic encourages childhood vaccination in Japan: findings from the VENUS study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparative biodistribution study of baculoviral and adenoviral vector based-vaccines against SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVID-19 hospitalisations amongst immunocompromised individuals receiving 300 mg AZD7442 (tixagevimab/cilgavimab) pre-exposure prophylaxis: real-world effectiveness data from Israel's largest health maintenance organisation

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitro IC₅₀ values predict SARS-CoV-2 neutralising antibody (nAb) titres

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVIDRIVE: a European public-private partnership for generating real-world evidence on the effectiveness of COVID-19 vaccines

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

High prevalence of immunocompromising conditions among patients with severe acute respiratory infection, including SARS-CoV-2: results from a multicentre, test-negative case-control study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Immunocompromise, cancer and other comorbidities in patients with severe acute respiratory infection testing positive versus negative for SARS-CoV-2: a post hoc analysis of COVIDRIVE data from May 2021 to May 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prospective study on clinical and biochemical parameters in post-COVID fatigue and myalgia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evaluation of a saliva home collection kit and temperature stability demonstrates the utility of home-collected saliva specimens for laboratory-based COVID-19 diagnostic testing

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical outcomes and safety of remdesivir use in hospitalised COVID-19 patients with and without severe renal impairment

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Can a correlate of protection against SARS-CoV-2 infection be established in cancer patients: a statistical modeling perspective

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Limited effectiveness of adding remdesivir to dexamethasone in COVID-19 pneumonia during the evolution of SARS-CoV-2: a comparative study using a clinical data warehouse

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Adding hyponatraemia to “rule-of-six” prediction tool improves performance in identifying hospitalised patients with COVID-19 at risk of adverse clinical outcomes

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Persisting differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Immunogenicity of a single booster dose of Soberana Plus (FINLAY-FR-1A) vaccine in adults with different previous history of COVID-19 vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

De-mystifying the double danger of COVID-19 and dengue co-infection in India

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Integrated severe acute respiratory infection (SARI) sentinel surveillance of influenza, SARS-CoV-2 and RSV in Serbia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparison of clinical characteristics and outcomes in candidemic patients with and without COVID-19: a multicentre, propensity score-matched analysis

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

SARS-CoV-2 Spike fusion peptide (FP) mutation P812S unique to the nasal compartment in a 101-day persistent infection shows infectivity reduction and context-dependent neutralisation evasion of vaccinee sera

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The high expression of PD-1 defines a subpopulation of T follicular helper cell responding to COVID-19 vaccine in humans

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cell-free DNA as a promising non-invasive marker for predicting critical COVID-19 cases: a pilot study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Usage of oral contraceptives among healthcare workers: impact on COVID-19 booster vaccine immunogenicity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Local and systemic reactogenicity after mRNA and protein-based COVID vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomised phase 2 trial (COV-BOOST)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Survival impact of comorbidities on the one-year mortality among hospitalised COVID-19 patients in a vaccinated Omicron-infected multicentre cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bivalent Omicron BA1 vaccine booster increases the breadth and potency of memory-B and T cell response and protects against emerging SARS-CoV-2 variants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hospital-acquired COVID-19 at The Northern Hospital, 2021-2022, an outcome and costs analysis

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Increased MP/CP co-infection in COVID-19 positive kidney transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Risk of severe COVID-19 in SARS-CoV-2 vaccinated individuals with hematologic malignancies: a nationwide cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comercial Sars-CoV-2 test: performance evaluation on bronchoaspirates and broncholavages

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Risk factors for SARS-CoV-2 infection among healthcare workers in 168 hospitals: a multi-centre study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Longitudinal shifts in gut microbiota during mild COVID-19 are linked to post-acute COVID-19 syndrome (PACS)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A Randomized, Double-Blinded, Cohort Clinical Trial on Evaluating the Safety and Immunogenicity of Sequential Immunization of Two Doses of Omicron Specific Inactivated COVID-19 Vaccines as Boosters in Adults

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Continued increased risk of COVID-19 hospitalisation and death in immunocompromised individuals despite receipt of ≥4 vaccine doses: updated 2023 results from INFORM, a retrospective health database study in England

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparison of COVID-19 vs non-COVID-19 patients without haematological malignancies treated for invasive pulmonary aspergillosis: a 5 years retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pulmonary function in patients with dyspnea in the post-acute phase of COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Healthcare resource use and overall costs of COVID-19 during the Omicron-predominant period in immunocompromised individuals: results from INFORM, a retrospective health database study in England

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tracking SARS-CoV-2 Omicron VOC and sub-variants in Odisha, India November 2021 to May 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prospects for reducing the risk of emergence of SARS-CoV-2 variants from infections in immunocompromised individuals: a modelling approach

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Optimising a novel treatment strategy for COVID-19-related ARDS: a randomised, placebo-controlled clinical trial on supplementary therapies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pooled analysis of randomised trials comparing the clinical efficacy of early treatments of COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Duration of viral shedding in immunocompromised patients with SARS-CoV-2 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical characteristics and outcomes of hospitalised patients with SARS-CoV-2 infection in three different epidemic periods, Milan, Italy

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A Phase 1, concentration-QTc analysis shows bemnifosbuvir does not alter cardiac repolarisation

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sotrovimab in severely ill COVID-19 immunocompromised patients: multicentre retrospective cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pharmacokinetics, safety, and tolerability of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, in participants with hepatic impairment

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The mRNA-1273 COVID-19 vaccine induces CD4+ T cell responses among solid organ transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Efficacy and safety of EDP-235 in non-hospitalised adults with mild or moderate COVID-19: results from the phase 2 SPRINT study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A decoy strategy of using plant-based virus-like-particles (VLPs) against SARS-CoV-2 Infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bayesian analysis of a randomised trial comparing the clinical efficacy of early treatments of COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Canadian healthcare and education workers' hesitance to receive original and bivalent COVID-19 vaccines

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Viral, immunologic, and laboratory evaluations in patients with and without post-acute sequelae of SARS-CoV-2 infection (PASC)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Fingerstick blood shows excellent correlation with plasma for SARS-CoV-2 antibody detection with a novel multiplex immunoassay

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Hamster model to evaluate post-COVID-19 condition treated with ensitrelvir: smell disorder

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bivalent COVID-19 vaccination enhances neutralising antibody responses against Omicron subvariants up to nine months, except for EG.5

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Detection and surveillance of SARS-CoV-2 genomic variants in Georgia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

SARS-CoV-2 vaccination is not associated with involuntary childlessness - results of a prospective multicentre cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety and immunogenicity of the investigational CV0501 mRNA COVID-19 vaccine administered to adults ≥18 years of age

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Post-acute symptoms of COVID-19 in healthcare workers: temporal course, impact on daily life, and therapeutic measures

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Characteristics and outcomes of old and oldest-old hospitalised patients with COVID-19 during the late phase of the pandemic in central Taiwan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Reduction of post-acute COVID-19 sequelae after SARS-CoV-2 wild-type infection in healthcare workers over a 30-month period

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2 Omicron vs Delta infection: a retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Wastewater monitoring as an early warning system for SARS-CoV-2 variants: a comparison of clinical and wastewater samples in Hesse, Germany, Sep 2021-Dec 2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rapid recovery from SARS-CoV-2 infection among immunocompromised children despite limited neutralising antibody response: a virologic and sero-immunologic analysis of a single-centre cohort

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long-term risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during Omicron

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Development of a high-sensitivity fluorescence in situ hybridisation method for detecting SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Recent COVID-19 is associated with reduced cytokine response to LPS ex vivo and in vivo

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Performance of a novel dual marker RT-qPCR-based whole-blood assay for the detection of SARS-CoV-2-reactive T cells

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Seroepidemiology of SARS-CoV-2 in a cohort of pregnant women in Kampala, Uganda

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evidence of exposure to the SARS-CoV-2 virus in UK healthcare workers who reported no known COVID-19 infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Live single-cycle SARS-CoV-2 vaccine elicits high protection and sterilising immunity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Real-world performance of a single-use, analyser-free, molecular point-of-care test for COVID-19 used in the emergency department: results of a prospective trial (ED-POC)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Investigating factors associated with the economic cost of healthcare worker COVID-19-related absenteeism

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Development and characterisation of a novel SARS-CoV-2 macrodomain (Mac1) targeting inhibitor

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long-term trajectories of COVID-19 symptoms and their associations with quality of life: results from the 2-year-follow-up of the prospective Predi-COVID study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical trajectory of post COVID-19 condition during different SARS-CoV-2 variant periods

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Surfaces environmental monitoring of SARS-CoV-2: loop mediated isothermal AMPlification (LAMP) and droplet digital PCR (ddPCR) in comparison with standard real time PCR (RT-PCR)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of treatment of COVID-19 with sotrovimab on post-acute COVID-19 syndrome: an analysis of national COVID cohort collaborative (N3C) data

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Quasi-species prevalence and evolution of mutations in SARS-CoV-2 variants in European COVID-19 cohorts

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalised patients during the first wave of COVID-19 (PEACH study)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A longitudinal description of the health-related quality of life among high-risk individuals with COVID-19: a Dutch multicentre observational cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Early initiation of combined therapy in severely immunocompromised patients with COVID-19: A retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Extended remdesivir use in haematological patients with malignancies and prolonged COVID-19 in omicron era: tolerance and outcomes

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dual SARS-CoV-2 infections: genomics-based approach for detection of SARS-CoV-2 co-infections and diverse viral populations

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ultrasonological predictors of severity of dengue in a teaching hospital in South India

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVID-19 and network medicine: utilising multi-omic approaches in response to future pandemics

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Persistent DNA methylation changes up to 7 months after SARS-CoV-2 infection: initial findings from population-based studies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Anti-RBD IgG titres after a primary vaccination course with BNT162b2 and after a third booster dose with a first-generation m-RNA vaccine in a cohort of people living with HIV

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dynamics of Streptococcus pneumoniae non-PCV13 lineages in Spain during SARS-CoV-2 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Unraveling the role of casein kinase II in the SARS-CoV-2 lifecycle: implications for host-targeted antiviral development

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical manifestations of SARS-CoV-2 infection in Omicron subvariants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Surveillance of invasive pulmonary aspergillosis in COVID and non-COVID patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

SARS-CoV-2 infection and re-infection by Delta and Omicron variants in a population with low vaccine coverage

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab in kidney transplant recipients in the Kraken variant (XBB.1.5) era: a single-centre experience

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Molecular epidemiology of Pneumocystis jirovecii in patients with and without COVID-19, based on real time PCR assay

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Effect of tixagevimab-cilgavimab on viral shedding kinetics in immunocompromised patients with breakthrough COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of multiple-dose remdesivir, a COVID-19 antiviral, on CYP3A4 activity: a clinical drug-drug interaction (DDI) study with midazolam

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A cost and resource utilisation study of COVID-19 patients treated in German tertiary care hospitals

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Divergent SARS-CoV-2-induced immunity signals in the upper and lower respiratory tract in severe COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Pharmacokinetics, safety, and tolerability of single-dose obeldesivir in healthy Japanese and Caucasian participants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prevalence of and factors associated with long COVID among diverse healthcare workers in the United Kingdom: a cross-sectional analysis of a nationwide study (UK-REACH)

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Characteristics and outcomes of hospitalised patients across five waves of the COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

SARS-CoV-2 point-of-care antibody testing: a cross sectional study in healthy people and individuals at high-risk for severe COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Use of antibiotics in patients hospitalised for COVID-19: no beneficial effect on clinical outcome or course of disease

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Increasing antimicrobial resistance rates in relation to antibiotic misuse and overuse during COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long-term impairment of working ability in subjects under 60 years of age hospitalised for COVID-19 at 2 years of follow-up: a cross-sectional study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparison of a novel concentration method for SARS-CoV-2 wastewater monitoring

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bacterial co-infection and secondary infection in SARS-CoV-2 (COVID-19) adult patients in a national tertiary infectious disease hospital

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Surveillance and detection of SARS-CoV-2 in four national university campuses, the UniCoV Project: apps, antigens, saliva, wastewater, and participation

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Brief cognitive assessment for long COVID-19 sequelae and its significance

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Dual antiviral therapy can be effective for treatment of protracted SARS-CoV-2 infection in immunocompromised hosts

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Sub-populations of critically ill COVID-19 patients exist with distinct antibody responses to SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Missed opportunities of early SARS-CoV-2 therapy among hospitalized patients: a retrospective observational cohort study, Milan, Italy

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety and tolerability of tocilizumab for COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety and tolerability of baricitinib for COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Epidemiology of bacterial co-infections in COVID-19 associated pulmonary aspergillosis patients in a tertiary-care teaching hospital in Mexico City.

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evaluation of the digital lightcycler in monitoring SARS-CoV-2 RNA in sewage

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of COVID-19 infection in quality of life of hospitalised patients with autoimmune conditions: experience from a single-center in Greece

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety of tocilizumab and baricitinib for treatment of COVID-19 in hospitalised patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Reinfection of SARS-CoV-2 variants in immunocompromised patients with prolonged or relapsed viral shedding

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Associations of COVID-19 control measures, the incidence of pneumonia and various respiratory pathogens in Finland, 2020-2023

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical characteristics and factors associated with in-hospital post-surgical mortality in COVID-19 patients at a tertiary care center in Karachi, Pakistan

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Changes in antibiotic consumption due to COVID-19 pandemic in tertiary-care hospitals in Costa Rica: a five year interrupted time series study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

T-cell mediated response and post-COVID-19 syndrome

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Antibiotic use in outpatients with COVID-19 diagnosed with point of care tests in an integrated healthcare network in Utah, USA

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evaluation of humoral immune responses against SARS-CoV-2 variants after receiving booster doses

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Adding a SARS-CoV-2 RT-PCR on a faecal sample to a RT-PCR on a nasopharyngeal sample augments diagnostic sensitivity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVID-19 and influenza- role of haematological parameters in assesing the disease severity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Is early empiric antibiotherapy in patients hospitalised in ward settings with COVID-19 pneumonia beneficial?

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Proteomic insights into the impact of COVID-19 on peripheral blood mononuclear cells in kidney transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Increased risk of invasive aspergillosis in immunocompromised patients with persistent SARS-CoV-2 viral shedding > eight weeks, a retrospective case-control study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The association of platelet-to-lymphocyte ratio with COVID-19 and acute ischemic stroke in admitted adult patients in Zamboanga City Medical Center

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in patients with multiple sclerosis on disease modifying therapies

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Increased risk of SARS-CoV-2 infection in professional settings, shops, shared transport, and leisure activities in a case-control study in France, 2020-2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparing the disease burden of COVID-19 in-patients with and without high risk factors for severe outcomes: a retrospective study using routine hospital data

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Genomic detection of SARS-CoV-2 reinfections in the SIREN cohort study: has the 90-day interval endured?

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Longitudinal anti-SARS-CoV-2 antibody responses reveal cross-reactive boosting following vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prevalence and impact of persistent symptoms following SARS-CoV-2 infections in UK healthcare workers in the SIREN cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Concomitant vaccination uptake of the COVID-19 booster and influenza vaccine in the United States during the 2021/22 and 2022/23 seasons

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of age on SARS-CoV-2 transmission in French households: comparison of Alpha and Omicron variants

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Tracking SARS-CoV-2 RNA in urban wastewater through diverse biomarkers

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Immunosupressive treatment and CD4/CD8 T-cell exhaustion impact SARS-CoV-2-specific adaptive responses after vaccination in solid organ transplant

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Genomic characterization of SARS-CoV-2 outbreak during international scientific workshop: evidence of cross-border transmission

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Different effect of anti-s monoclonal antibodies on immunity depending on SARS-CoV-2 vaccination status

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Enhanced SARS-CoV-2 surveillance in Slovenia through wastewater analysis: a comprehensive community-level approach

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety of a self-amplifying mRNA COVID-19 vaccine, ARCT-154

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Treatment strategies to avoid residents' isolation in nursing home: modelling analysis

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The impact Of COVID-19 on healthcare utilization associated with antibiotic resistance among inpatients at a tertiary hospital in Vietnam

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nasopharyngeal microbial dysbiosis in COVID-19 patients revealed by 16S metagenomics

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

IgG anti SARS-CoV-2 spike levels and vaccination on a cohort of hospital healthcare workers

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Multi-tissue immune analysis of severe COVID-19 patients indicates differential adaptive immune response enrichment in secondarylymphoid tissues

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

SARS-CoV-2 infection accompanied by gastrointestinal symptoms elicits antibodies with significantly higher avidity as compared to infections without gastrointestinal symptoms

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

A polymersome COVID-19 booster is safe and immunogenic in pre-vaccinated healthy volunteers and confers exceptional thermostability

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Ceftazidime-avibactam in the treatment of bacterial superinfection in COVID-19 patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Infection of macrophages by SARS-CoV-2: implications for viral spreading and immune response

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Machine learning models based on exhaled volatile organic compounds combined with serum cytokine profile for severity prediction in COVID-19 and other respiratory infections

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVID-19 mRNA vaccines may also boost immunity to seasonal coronaviruses and influenza

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Is there still room for COVID-19 pre-exposure prophylaxis? A real-world case-control effectiveness study in high-risk patients with hematologic malignancies during the emerging Omicron surge

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety and immunogenicity of SARS-CoV-2 mRNA-based vaccines in a cohort of lung transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Long COVID among people living with HIV (PLWH): a real-life study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Diffuse transcriptional upregulation of human endogenous retroviruses in the bronchoalveolar lavage fluid of patients with severe COVID-19 pneumonia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of COVID-19 on the incidence of nosocomial pneumonia in two intensive care units

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Complicating bacterial pulmonary infections in critical COVID-19 pneumonia

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Prediction of transmission inhibition based on the antiviral effect of ensitrelvir and simulation of its impact on epidemics

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evolutionary timeline of SARS-CoV-2

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Cross-neutralising activity and durability of antibody responses against BA.4/5 and XBB 1.5 variant after BA.4/5 bivalent vaccination according to the previous SARS-CoV-2 infection: a three-month prospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Adaptive immunity-derived epitope profiles as indicators of COVID-19 severity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of the COVID-19 pandemic on the resistance of bacterial agents isolated from the lower respiratory tract in ICU patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparative analysis of symptom profile and risk of death associated with infection by SARS-CoV-2 and its variants in Hong Kong

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Immunogenicity of SARS-CoV-2 mRNA-based vaccines in a cohort of lung and liver transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Driving selection of target populations to design RCT assessing therapies for the prevention and treatment of the post-COVID-19 syndrome

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Estimating the effect of vaccination and previous infection on Ct values as a proxy of viral load

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Neurosensorial cluster of the post-COVID 19 syndrome: prospective psychophysical assessment of smell and taste impairment and impact on quality of life

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Comparative effectiveness of the mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: a systematic literature review and meta-analysis using the GRADE framework

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Safety and immunogenicity of SARS-CoV-2 mRNA-based vaccines in a cohort of liver transplant recipients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Monitoring protection from SARS-CoV-2 infection and COVID-19 vaccination in the UK SIREN healthcare worker cohort 2020-2024: assessing the impact of vaccine boosters

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

In-house software development reveals insights into 'closed system' diagnostics - a lesson from rapid development of high-throughput SARS-CoV-2 screening

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Bio-humoral characterisation of patients by clusters of post-COVID-19 syndrome at 18-month follow-up: the multicentre, prospective ORCHESTRA study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Seroprevalence of Omicron BA.2 neutralising antibodies among residents in residential care homes for the elderly in Hong Kong, February – November 2022

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Effectiveness and safety of favipiravir versus standard of care in adult COVID-19 patients in a tertiary hospital setting: a retrospective cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Impact of COVID-19 on home healthcare agencies and nursing homes in the United States

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Reduction of post COVID-19 condition during the Omicron wave: results from the EuCARE POSTCOVID Study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Increasing prevalence of comorbidities in patients hospitalised with COVID-19 across variant eras

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Rates of long COVID-related symptoms and diagnoses in patients hospitalised with COVID-19 increased across variant eras

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Risk factors for morbidity and mortality among adult patients with COVID-19 and pulmonary tuberculosis co-infection admitted at a national infectious disease referral hospital in Manila, Philippines

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Gut microbiota composition in COVID-19 patients during the Delta and Omicron variant predominance in Uzhhorod, Ukraine

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a multicentre observational cohort study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical prediction model for bacterial coinfection in hospitalised COVID-19 patients during four waves of the pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Expansion of the laboratory surveillance of respiratory viruses in the Philippines: a response to the COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Identification of new host-directed antiviral targets by proteome analysis of cysteamine anti-SARS-CoV-2 activity

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evaluation of SARS-CoV-2 spike mutations in immunocompromised and immunocompetent patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Remdesivir 30-days-COVID-19-related mortality, length of hospitalization and time until negative swab test in severely immunocompromised patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nirmatrelvir/ritonavir in the management of COVID-19: a retrospective study in a highly vaccinated population

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Distinct variation pattern between consensus sequences and mutant spectra during the COVID-19 pandemic

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Extinction of SARS-CoV-2 by synergistic lethal mutagenesis exerted by remdesivir and ribavirin

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Independent online medical education significantly increases physician knowledge and confidence regarding real-world data for COVID-19 antiviral therapy in high-risk patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Antiviral use in mild to moderate SARS-CoV-2 infections during the Omicron wave in geriatric patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Resurgence of SARS-CoV-2 viral load following antiviral therapy cessation in haematologic patients with COVID-19

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nasopharyngeal microbiome in COVID-19 infection.

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Investigating the impact of vaccination and reinfection dynamics on the XBB variant of SARS-CoV-2 ???

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Nirmatrelvir/ritonavir or remdesivir for COVID-19 in patients with B-cell malignancies and plasma cell dyscrasias

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Determinants of recorded SARS-CoV-2 vaccine uptake among ART-compliant people living with HIV

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Discordant results in the Xpert® Xpress SARS-CoV-2/ Flu/RSV assay: The importance of an accurate assessment at curve analysis in PCR testing

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Type I interferon pathway-related hub genes as a potential therapeutic target for SARS-CoV-2 omicron variant-induced symptoms

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Multicomplex pharmacophore based virtual screening, docking, and molecular dynamics to discover novel inhibitors against main protease (Mpro) of coronaviruses

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Monitoring anti-SARS-CoV-2 antibodies and variant-specific neutralization in healthy children by dried blood spots

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Clinical epidemiology and biomarker identification in patients with novel coronavirus infection (severe/critical) secondary to bacterial infection

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Risk of SARS-CoV-2 infection and severe COVID-19 in haematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation during Omicron BA.5 dominated wave

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Global rate of antibiotic use, co-infections, resistance and clinical outcomes in COVID-19 patients receiving antibiotics in 65 countries worldwide

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Anion exchange woven fabric ensures a most efficient concentration of SARS-CoV-2 from wastewater

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Increased viral loads of Omicron EG.5.1 compared to co-circulating SARS-CoV-2 lineages

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Broad immunity to SARS-CoV-2 mediated by a Vaccine Formulation Based on the receptor binding domain (RBD)-Nucleoprotein cocktail Co-Administered with an AddaVax adjuvant

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Surveillance of SARS-COV2 variants in wastewater of aircraft

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Household transmission dynamics of SARS-CoV-2 in the north of the Netherlands: the COVID-HOME study

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Evaluation of immune response to anti-SARS-CoV-2 vaccination in cancer patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

COVID-19 does not increase the risk of invasive fungal infection in hematopoietic stem-cell transplanted patients

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Coinfection of SARS-Cov-2 with other respiratory viruses in a large cohort study: the UnCoVER-Brazil project

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Lessons for future pandemic preparedness: The SIREN experience

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Promotion of SARS-CoV-2 vaccination in at-risk sectors: methods and impact of an intervention in jail health care

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Concomitant administration of seasonal influenza and COVID-19 mRNA

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

T cell receptor sequencing allows monitoring longitudinal T cell clonal responses and antigen-specificity to COVID-19 vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

The acquisition of SARS-CoV-2 immunity from sequential Spike exposures via infection or vaccination

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Post-acute sequalae of COVID-19 three to twelve months after infection: Delta versus Omicron

27/04 12:00

1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Urine collection practices analysis and the impact of boric acid tubes on quantitative urinary bacterial cultures in hospitalised patients

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Pre-analytical delays in blood culture pathway do not always postpone actionable results

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

GDH/toxin assay plus PCR vs PCR for the diagnosis and treatment of Clostridioides difficile infection

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Urine culture reflex implemented to reduce inappropriate testing and treatment of UTIs

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Can IgM predict IgG avidity values for Toxoplasma and CMV?

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Same-day reporting of blood cultures in gram-negative sepsis: achieving holy grail of microbiology sans MALDI-TOF

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Development of a cost-effective rapid detection of carbapenem-resistance Gram-negative bacteria laboratory workflow

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Preliminary evaluation of a rapid lateral flow immunoassay for the detection of Candida albicans, Trichomonas vaginalis, or Gardneralla vaginalis antigen kit using clinical vaginal swab specimens

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Evaluation of a novel chromogenic culture medium for the detection and enumeration of Pseudomonas aeruginosa

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Evaluation of the analytical and clinical performance of a new diagnostic test for the detection of Campylobacter antigens in stool specimen

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Performance comparison of a new GDH antigen chemiluminescent immunoassay for the diagnosis of Clostridioides difficile infection

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Blood volume is the key determinant of paediatric blood culture performance: results from a pre- and post-intervention study

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Impact of laboratory processing delays on microbiological diagnostics

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Rates of Gram-positive blood culture contamination in El Paso Texas: a comparative assessment between nuclic acid diagnostic test & conventional method

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Blood cultures in resource-limited settings: extended stability testing in simulation experiments

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

The impact of implementing a new blood culture system for coagulase-negative staphylococci contamination

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Enhancing microbiology laboratory organisation: first WASPLab installation in Romania

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Efficient ELISA tests for early diagnosis of plague

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Direct Gram staining replaced by a flow cytometer automate to save time

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Evaluation of laser light scattering method for urine culture screening in outpatients

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Comparing optical microscopy with table-top scanning electron microscopy in a clinical bacteriology laboratory: a cost-effectiveness analysis

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)

Evaluation of a 16 hour incubation for urine culture using wasp/wasplab imaging analysis

27/04 12:00

4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)